Needham Keeps Their Buy Rating on Selecta Biosciences (SELB)

By Austin Angelo

Needham analyst Chad Messer maintained a Buy rating on Selecta Biosciences (SELBResearch Report) today and set a price target of $5.00. The company’s shares closed last Thursday at $3.02.

According to, Messer is a 5-star analyst with an average return of 10.7% and a 47.0% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Selecta Biosciences with a $7.83 average price target, which is a 152.6% upside from current levels. In a report issued on April 28, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $8.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.83 and a one-year low of $1.28. Currently, Selecta Biosciences has an average volume of 778.9K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SELB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.